1. Oncology Society of Chinese Medical Association, Journal of Chinese Medical Association. Oncology Society of Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2021 edition). Natl Med J China, 2021, 101: 1725–1757 [中华医学会肿瘤学分会, 中华医学会杂志社. 中华医学会肿瘤学分会肺癌临床诊疗指南(2021版) (in Chinese). 中华医学杂志, 2021, 101: 1725–1757].
2. Geng R X, Zheng Z B, Dai X Y. Immune checkpoint inhibitors in solid tumors (in Chinese). Sci Sin Vitae, 2021, 51: 1180-1192.
3. Chinese Society of Nutritional Oncology, Key Laboratory of State Administration for Market Regulation (Special Medical Food for Cancer), Cong M H, Shi H P. Consensus of Chinese experts on exercise therapy for cancer patients (in Chinese). Sci Sin Vitae, 2022, 52: 587–602 [中国抗癌协会肿瘤营养专业委员会, 国家市场监管重点实验室, 丛明华, 石汉平. 中国恶性肿瘤患者运动治疗专家共识. 中国科学: 生命科学, 2022, 52: 587–602].
4. Allemani C, Matsuda T, Di Carlo V. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37513025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet, 2018, 391: 1023-1075.
5. Zeng H, Chen W, Zheng R. Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries. Lancet Glob Health, 2018, 6: e555-e567.